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Introduction: The phosphotidylinositol-3 kinase/serine-threonine 
kinase (AKT)/mammalian target of rapamycin signaling pathway 
is frequently altered in non–small-cell lung cancer (NSCLC). 
PX-866 is an oral, irreversible, pan-isoform inhibitor of phos-
photidylinositol-3 kinase. Preclinical models revealed synergy 
with docetaxel and a phase 1 trial demonstrated tolerability of this 
combination. This randomized phase 2 study evaluated PX-866 
combined with docetaxel in patients with advanced, refractory 
NSCLC.
Methods: Patients with locally advanced, recurrent, or metastatic 
NSCLC who had received at least one and no more than two prior 
systemic treatment regimens were randomized (1:1) to a combination 
of docetaxel (75 mg/m2 intravenous every 21 days) with or without 
PX-866 (8 mg orally daily; arms A and B, respectively). The primary 
end point was progression-free survival (PFS). Secondary end points 
included objective response rate, overall survival (OS), toxicity, and 
correlation of biomarker analyses with efficacy outcomes.
Results: A total of 95 patients were enrolled. Median PFS was 
2 months in arm A and 2.9 months in arm B (p = 0.65). Objective 
response rates were 6% and 0% in arms A and B, respectively 
(p = 0.4). There was no difference in OS between the two arms (7.0 
versus 9.2 months; p = 0.9). Grade 3 or higher adverse events were 
infrequent, but more common in the combination arm with respect 
to diarrhea (7% versus 2%), nausea (4% versus 0%), and vomiting 
(7% versus 0%). PIK3CA mutations or PTEN loss were infrequently 
observed.
Conclusion: The addition of PX-866 to docetaxel did not improve 
PFS, response rate, or OS in patients with advanced, refractory 
NSCLC without molecular preselection.
Key Words: PIK3CA, Phosphotidylinositol-3 kinase, Docetaxel, 
Combination therapy, Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 1031–1035)
The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin signaling 
pathway is frequently altered in human cancers, leading to 
cell proliferation, increased expression of survival genes, and 
decreased expression of proapoptotic signals.1 In non–small-
cell lung cancer (NSCLC), the PI3K pathway may play a role 
in cancer proliferation and response to therapy, particularly 
in squamous cell carcinomas.2 This can occur by means of 
PIK3CA activation, mutation, or amplification; PTEN loss; 
or up-regulation of upstream tyrosine kinases.3 PX-866 is a 
novel oral, pan-isoform inhibitor of PI3K.4 In a phase 1 study, 
both PX-866 and docetaxel were given at their single-agent 
maximal tolerated doses in patients with advanced cancers.5 
The majority of adverse events (AEs) were gastrointestinal 
and grade 2 or lower similar to the single-agent PX-866 trial.6 
Therefore, we conducted an open-label, randomized, phase 2 
trial comparing docetaxel alone versus docetaxel plus PX-866 
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in patients with relapsed/metastatic (R/M) NSCLC in the 
 second- or third-line setting.
MATERIALS AND METHODS
Eligibility Criteria
Subjects had R/M NSCLC for which they had received 
one to two prior systemic therapies, including up to one 
platinum-based chemotherapy regimen. Other key inclusion 
criteria were age 18 years or older, measurable disease by 
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 
criteria,7 Eastern Cooperative Oncology Group performance 
status 0 to 1, life expectancy 3 months or more, and adequate 
hematologic, hepatic, and renal function. Treatment with 
any systemic anticancer or radiation therapy was prohibited 
within 4 weeks of study drug dosing. Patients with adequately 
treated and stable brain metastases were eligible. Salient 
exclusion criteria included known HIV infection; medical, 
social, or psychological factors affecting safety or compli-
ance; grade 2 or higher neuropathy; history of hypersensitiv-
ity to docetaxel or other drugs formulated with polysorbate; 
pregnant/breastfeeding; prior docetaxel for R/M NSCLC or 
within 6 months of enrollment in the curative setting; or any 
prior treatment with a PI3K inhibitor. Each center’s institu-
tional review board granted approval and written informed 
consent was mandatory.
Treatment and Efficacy Assessments
Patients were randomized to PX-866 8 mg by mouth 
daily with docetaxel 75 mg/m2 intravenous once every 21 days 
or docetaxel 75 mg/m2 intravenous once every 21 days alone in 
a 1:1 manner without stratification factors. Colony-stimulating 
factors and antiemetics were permitted in any cycle according 
to institutional guidelines. All patients received dexametha-
sone 8 mg orally twice daily for 3 days starting the day before 
docetaxel administration. Patients were evaluated for pro-
gression every two cycles. Patients continued therapy as long 
as they had stable disease or better per RECIST 1.1 criteria 
and lacked unacceptable toxicity or withdrawal of consent. 
Patients in the combination arm were allowed to continue 
PX-866 alone after discontinuation of docetaxel.
Safety Assessment
Safety assessments included vital signs, laboratory 
assessments, and physical examinations. AEs were assessed 
using the National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.02. Up to two dose 
reductions were allowed for docetaxel (60 and 45 mg/m2) 
and three dose reductions for PX-866 (6, 4, and 2 mg/day). 
Subjects requiring additional dose reductions of PX-866 were 
removed from study. Study drugs were discontinued if treat-
ment needed to be delayed by more than 2 weeks.
Biomarker Measurements
Optional archival tumor specimens were evaluated for 
PIK3CA and KRAS mutations and PTEN expression by immu-
nohistochemistry as previously described.5,6
Statistics
The primary end point of this study was progression-
free survival (PFS) and secondary end points were objective 
response rate (ORR), incidence and severity of AEs, overall 
survival (OS), and exploratory end points of biomarker cor-
relations with efficacy. A docetaxel-alone control of median 
PFS of 3 months was assumed for the NSCLC study popula-
tion. With a one-sided 0.20 false-positive error rate, a projected 
1-year enrollment period with an additional 0.5 years of fol-
low-up before analysis and a control over experimental hazard 
ratio of 1.5, a total of 80 patients were required for the log-rank 
test with 0.80 power to detect a statistically significant ben-
efit of the combination arm of PX-866 plus docetaxel versus 
docetaxel alone. Assuming a drop-off rate of 10%, a total of 
88 patients (44 per arm) with NSCLC were targeted to enroll.
RESULTS
Patient Characteristics
Ninety-five patients were enrolled between November 
2011 and July 2012. Of these, 48 and 47 patients were ran-
domized to the PX-866 plus docetaxel (arm A) and docetaxel-
alone group (arm B), respectively. Baseline characteristics 
were well balanced between the two arms excluding histology 
(χ2 test, p = 0.04) and sex (χ2 test, p = 0.08; Table 1). The 
TABLE 1.  Patient Demographics
PX-866 + Docetaxel 
(n = 48)
Docetaxel  
(n = 47)
Median age (range) 65 (44–84) 60 (35–84)
Sex
  Female 15 (31%) 23 (49%)
  Male 33 (69%) 24 (51%)
Ethnicity
  Caucasian 39 (81%) 34 (72%)
  African American 5 (10%) 3 (6%)
  Other 4 (8%) 10 (21%)
ECOG
  0 14 (29%) 12 (26%)
  1 34 (71%) 35 (75%)
Histology
  Adenocarcinoma 34 (71%) 24 (51%)
  Squamous 8 (17%) 12 (26%)
  Other 6 (13%) 11 (23%)
Stage at diagnosis, % I/II/III/IV 2/2/25/71 2/4/23/70
Stage at baseline, III/IV, N (%) 3 (6%)/45 (94%) 2 (4%)/45 (96%)
Prior anticancer therapy 47 (98%) 47 (100%)
  Systemic therapy 39 (81%) 41 (87%)
  Radiotherapy 10 (21%) 11 (23%)
  Systemic/radiotherapy 17 (35%) 11 (23%)
No. of prior systemic therapies, 
mean/range
1.8 (1–7) 1.5 (1–5)
Median time since diagnosis, 
months
10.8 10.9
ECOG, Eastern Cooperative Oncology Group.
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groups were similar with respect to numbers of prior systemic 
therapies and median time since diagnosis.
Treatment Delivered
In arm A, 45 patients (94%) received at least one dose 
of PX-866 and/or docetaxel, whereas 47 patients (94%) in 
arm B received at least one dose of docetaxel (Fig. 1). The 
median number of docetaxel cycles administered was 2 
(range, 1–16) and 3.5 (range, 1–16) in arms A and B, respec-
tively. Ten patients experienced docetaxel dose interruptions 
or modifications (3 in arm A and 7 in arm B). Twenty-seven 
patients (60%) experienced a total of 52 dose interruptions or 
modifications of PX-866, with 35 (67%) disruptions due to 
AEs. The most common reasons for dose disruptions include 
diarrhea (n = 6) and pneumonia (n = 3). A total of 58 patients 
(29 in each arm) were taken off study because of disease 
progression.
Efficacy Evaluation
Seventy patients (74%) were evaluable for response as 
measured by RECIST 1.1 (34 in arm A and 36 in arm B). 
There was no difference in ORR (complete response plus 
partial responses; p = 0.12) or disease control rate (complete 
response + partial response + stable disease after 2 cycles; 
p = 0.97) between the two arms (Table 2). Median PFS was 
2 months (95% confidence interval [CI], 1.6–2.9) for arm 
A and 2.9 months (95% CI, 1.6–4.8) for arm B (p = 0.65; 
Fig. 2). Median OS was 7.9 months in arm A (95% CI, 
4.5–11.1) and 9.4 months in arm B (95% CI, 6.1 to not 
reached; p = 0.9; Fig. 3). Of the 50 patients whose archival 
tumors were analyzed, four patients had PIK3CA mutations 
(3 in arm A and 1 in arm B), whereas seven patients had 
KRAS mutations (4 in arm A and 3 in arm B). PTEN expres-
sion was reduced or absent in nine patients (3 in arm A and 
6 in arm B). PIK3CA mutation, KRAS mutation, and PTEN 
immunohistochemistry could not be correlated with PFS, 
ORR, or OS because of their rarity.
FIGURE 1.  CONSORT diagram showing the progress of 
patients though the trial, adapted from Begg et al, Improving 
the quality of reporting of randomized controlled trials. The 
CONSORT statement. JAMA 1996;276:637–639.
TABLE 2.  Response Rate
PX-866 + Docetaxel 
(n = 48)
Docetaxel 
(n = 47)
CR 0 0
PR 3 (6%) 0 (0%)
SD 14 (29%) 25 (53%)
Progressive disease 17 (35%) 9 (19%)
Not evaluable 14 (29%) 13 (28%)
Disease control rate (CR/PR/SD) 17 (35%) 25 (53%)
Response rate represent best overall response rate (investigator).
CR, complete response; PR, partial response; SD, stable disease.
FIGURE 2.  Kaplan–Meier curves for progression-free survival (days). NSCLC, non–small-cell lung cancer.
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Safety and Tolerability
Eighty-nine enrolled patients received at least one treat-
ment on protocol and were considered evaluable for safety. In 
both arms, most AEs were 2 or less (Table 3). There seemed 
to be more all-grade toxicity in arm A including diarrhea 
(76% versus 25%), nausea (56% versus 30%), vomiting (42% 
versus 21%), anorexia (40% versus 18%), and fatigue (62% 
versus 43%). However, there were few grade 3 or higher AEs 
in either arms excluding neutropenia (9% and 25% in arms 
A and B, respectively). No patients in arm A withdrew due 
to AEs, whereas five patients in arm B were taken off study 
because of toxicity.
DISCUSSION
The addition of PX-866 to docetaxel failed to improve 
PFS, ORR, or OS in patients with R/M NSCLC. Both clinical 
FIGURE 3.  Kaplan–Meier curves for over-
all survival (days). NSCLC, non–small-cell 
lung cancer.
TABLE 3.  Selected Adverse Events
Adverse Event
PX-866 ± Docetaxel (n = 45) Docetaxel Alone (n = 44)
All Grades Grade ≥3 All Grades Grade ≥3
Hematological
  Anemia 7 (16%) 2 (4%) 10 (23%) 3 (7%)
  Neutropenia 14 (31%) 4 (9%) 15 (34%) 11 (25%)
  Thrombocytopenia 2 (4%) 1 (2%) 0 (0%) 0 (0%)
  Febrile neutropenia 4 (9%) 4 (9%) 4 (9%) 4 (9%)
Nonhematological
 Abdominal pain 8 (18%) 2 (4%) 3 (17%) 1 (2%)
 Diarrhea 34 (76%) 3 (7%) 12 (25%) 1 (2%)
 Constipation 10 (22%) 0 (0%) 10 (22%) 1 (2%)
 Nausea 25 (56%) 2 (4%) 13 (30%) 0 (0%)
 Stomatitis 5 (11%) 0 (0%) 7 (16%) 1 (2%)
 Vomiting 19 (42%) 3 (7%) 9 (21%) 0 (0%)
 Fatigue 28 (62%) 2 (4%) 19 (43%) 1 (2%)
 Anorexia 18 (40%) 0 (0%) 8 (18%) 0 (0%)
 Peripheral edema 9 (20%) 1 (2%) 9 (20%) 0 (0%)
 Arthralgia 7 (15%) 0 (0%) 9 (18%) 0 (0%)
 Peripheral neuropathy 4 (9%) 1 (2%) 2 (5%) 0 (0%)
 Cough 9 (20%) 0 (0%) 6 (14%) 1 (2%)
 Dyspnea 10 (22%) 4 (9%) 3 (7%) 1 (2%)
 Alopecia 8 (18%) 0 (0%) 8 (18%) 0 (0%)
 Rash 9 (20%) 0 (0%) 2 (5%) 0 (0%)
 Transaminitis 5 (11%) 0 (0%) 0 (0%) 0 (0%)
 Hyperglycemia 1 (2%) 0 (0%) 2 (5%) 1 (2%)
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and biological reasons may account for the lack of benefit. The 
imbalance between adenocarcinoma histology and female sex, 
both favorable prognostic factors, may have confounded the 
results8,9; however, each arm had an increased proportion of 
one of these favorable factors, so it is difficult to fully explain 
the study findings based on these imbalances. Perhaps a more 
compelling explanation for the lack of clinical benefit rests in 
the patients’ tumor biology which revealed very few genetic 
alterations (PIK3CA mutations, PTEN loss) thought to predict 
sensitivity to PI3K inhibitors. Although it has been difficult 
to identify predictive biomarkers across all tumor types for 
this class of drugs, preclinical data suggest that PI3K path-
way activation may correlate with sensitivity to PI3K inhibi-
tors.10–13 Given that the frequencies of these alterations are 
influenced by the underlying histology and are more common 
in squamous cell carcinoma, under-representation of patients 
with squamous cancers may have contributed to the negative 
outcome.
Although the addition of PX-866 to docetaxel was rea-
sonably well tolerated, all-grade toxicity seemed to be more 
pronounced in the combination arm. Many of AEs are con-
sistent with other phase 1/2 studies evaluating PI3K inhibi-
tors including our own phase 1 study.5 Of note, there are 
few studies with reported safety outcomes evaluating PI3K 
inhibitors in combination with docetaxel, and our study adds 
substantial experience with this combination. To date, rash, 
hyperglycemia, and transaminase elevations seem to be class 
effects of PI3K/AKT/mammalian target of rapamycin inhibi-
tion, although gastrointestinal side effects have been reported 
in studies as well.14 Interestingly, despite more frequent AEs 
in the combination arm, no patients were taken off study 
because of toxicity in this arm suggesting that the toxicity was 
manageable.
In summary, the addition of PX-866 to docetaxel did 
not improve clinical outcomes over docetaxel alone for a 
molecularly unselected population of patients with R/M 
NSCLC. Despite these negative results, the scientific ratio-
nale in a target-selected population remains compelling, and 
further studies investigating inhibition of this pathway in 
NSCLC should be carried out. Investigations should focus 
on appropriate biomarker or histology selection to optimize 
clinical benefit.
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